The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Acetylon Pharmaceuticals; Amgen; Celgene
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Merck; Sanofi
Speakers' Bureau - Amgen; Celgene; Takeda
Research Funding - Acetylon Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celgene; Karyopharm Therapeutics; Merck; Sanofi
Expert Testimony - Celgene; Takeda

Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
 
Joseph Mikhael
Research Funding - Abbvie (Inst); Celgene (Inst); Sanofi (Inst)
 
Paul G. Richardson
Consulting or Advisory Role - Celgene; Janssen; Takeda
Research Funding - Celgene; Takeda
 
Saad Zafar Usmani
Consulting or Advisory Role - Amgen; Celgene; Janssen Oncology
Speakers' Bureau - Amgen; Celgene; Takeda
Research Funding - Array BioPharma; Celgene; Janssen Oncology; Millennium; Onyx; Pharmacyclics; Sanofi
 
Noopur S. Raje
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst)
 
William Bensinger
No Relationships to Disclose
 
Franck Dubin
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Qianying Liu
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Olivier Vitse
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Kenneth Carl Anderson
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Millennium
Patents, Royalties, Other Intellectual Property - C4 Therapeutics; Oncopep